Previous 10 | Next 10 |
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-03-08 12:11:45 ET More on IDEAYA, Immunocore, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Ideaya Biosciences: A Strong Bet In Targeted Oncology Immunocore Holdings: Vulnerable To Profit Taking After Big Rally Immunocore to work w...
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events PR Newswire SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development ...
2024-03-02 18:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-21 11:30:02 ET RBC Capital analyst issues BUY recommendation for IDYA on February 21, 2024 11:01AM ET. The previous analyst recommendation was Buy. IDYA was trading at $44.24 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
2024-02-20 09:52:37 ET More on IDEAYA Biosciences Ideaya Biosciences: A Strong Bet In Targeted Oncology Ideaya Biosciences Stock: An Opportunity Missed (Rating Downgrade) Seeking Alpha’s Quant Rating on IDEAYA Biosciences Historical earnings data for I...
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update PR Newswire Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2...
2024-02-16 12:56:07 ET Summary IDEAYA Biosciences' stock has increased by 57% since September, outperforming the S&P 500. PRMT5 inhibitors have gained attention in the biotech industry, with Bristol Myers paying $5.8 billion, in part, for Mirati's PRMT5 medication. IDEAYA'...
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the disco...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.7% on the day to $25.75. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted the...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...